711|0|Public
5|$|Aspirin {{is known}} to {{interact}} with other drugs. For example, acetazolamide and ammonium chloride are known to enhance the intoxicating effect of salicylates, and alcohol also increases the gastrointestinal bleeding associated with these types of drugs. Aspirin {{is known to}} displace a number of drugs from protein-binding sites in the blood, including the antidiabetic drugs <b>tolbutamide</b> and chlorpropamide, warfarin, methotrexate, phenytoin, probenecid, valproic acid (as well as interfering with beta oxidation, {{an important part of}} valproate metabolism), and other NSAIDs. Corticosteroids may also reduce the concentration of aspirin. Ibuprofen can negate the antiplatelet effect of aspirin used for cardioprotection and stroke prevention. The pharmacological activity of spironolactone may be reduced by taking aspirin, and it is known to compete with penicillin G for renal tubular secretion. Aspirin may also inhibit the absorption of vitamin C.|$|E
25|$|Clinically {{significant}} {{drug interactions}} with the CYP1A2 substrate theophylline, the CYP2C9 substrate <b>tolbutamide,</b> the CYP2D6 substrate desipramine, and the CYP3A4 substrate triazolam have all been demonstrated with cimetidine, and interactions with other substrates of these enzymes are likely as well.|$|E
25|$|CYP2C9 {{constitutes}} {{the majority of}} the CYP2C subfamily, representing approximately 20% of the liver content. It is involved in the metabolism of approximately 10% of all drugs, which include medications with narrow therapeutic windows such as warfarin and <b>tolbutamide.</b> There are approximately 57 genetic variants associated with CYP2C9.|$|E
25|$|Sertraline had {{a slight}} {{inhibitory}} effect on the metabolism of diazepam, <b>tolbutamide</b> and warfarin, which are CYP2C9 or CYP2C19 substrates; this effect was {{not considered to be}} clinically relevant. As expected from in vitro data, sertraline did not alter the human metabolism of the CYP3A4 substrates erythromycin, alprazolam, carbamazepine, clonazepam, and terfenadine; neither did it affect metabolism of the CYP1A2 substrate clozapine.|$|E
50|$|Salicylates {{displace}} <b>tolbutamide</b> {{from its}} binding site on plasma binding proteins {{which lead to}} increase in free <b>tolbutamide</b> concentration, thus hypoglycemic shock.|$|E
50|$|<b>Tolbutamide</b> is a first-generation {{potassium}} channel blocker, sulfonylurea oral hypoglycemic medication. This drug {{may be used}} in the management of type 2 diabetes if diet alone is not effective. <b>Tolbutamide</b> stimulates the secretion of insulin by the pancreas.|$|E
5000|$|First-generation sulfonylureas, e.g. <b>tolbutamide</b> and {{chlorpropamide}} ...|$|E
5000|$|Sulfonylurea {{antidiabetic}} {{drugs such}} as glibenclamide, chlorpropamide and <b>tolbutamide</b> ...|$|E
5000|$|First {{generation}} drugs include acetohexamide, carbutamide, chlorpropamide, glycyclamide (tolhexamide), metahexamide, tolazamide and <b>tolbutamide.</b>|$|E
50|$|Due to its {{affinity}} to {{the liver}} enzyme CYP2C9, interactions with drugs being metabolised by this enzyme are also possible, but unlikely. No interaction with <b>tolbutamide,</b> a 2C9 substrate, {{was observed in}} studies.|$|E
5000|$|Clinically {{significant}} {{drug interactions}} with the CYP1A2 substrate theophylline, the CYP2C9 substrate <b>tolbutamide,</b> the CYP2D6 substrate desipramine, and the CYP3A4 substrate triazolam have all been demonstrated with cimetidine, and interactions with other substrates of these enzymes are likely as well.|$|E
50|$|No {{systematic}} interaction {{studies are}} available. The enzyme inducers phenobarbital and phenytoin {{have been found}} to lower its blood plasma concentrations. Theoretically possible interactions include increased plasma concentrations when combined with sodium salicylate, sulfamethizole or <b>tolbutamide,</b> which displace teniposide from plasma protein binding, at least in vitro.|$|E
50|$|CYP2C9 {{constitutes}} {{the majority of}} the CYP2C subfamily, representing approximately 20% of the liver content. It is involved in the metabolism of approximately 10% of all drugs, which include medications with narrow therapeutic windows such as warfarin and <b>tolbutamide.</b> There are approximately 57 genetic variants associated with CYP2C9.|$|E
50|$|Glicaramide (SQ-65993) is an orally {{bioavailable}} anti-diabetic medication. It has {{a similar}} potency as glibenclamide (glyburide) {{in the class of}} medication known as sulfonylureas. Its structure is similar since it has a cyclic acyl group which replaces the latter's 2-methoxy-5-chlorobenzyl. Same as glibenclamide, it is classified as a second-generation sulfonylurea. It may have more pronounced extra-pancreatic effects than glibenclamide or <b>tolbutamide.</b>|$|E
50|$|Sertraline had {{a slight}} {{inhibitory}} effect on the metabolism of diazepam, <b>tolbutamide</b> and warfarin, which are CYP2C9 or CYP2C19 substrates; this effect was {{not considered to be}} clinically relevant. As expected from in vitro data, sertraline did not alter the human metabolism of the CYP3A4 substrates erythromycin, alprazolam, carbamazepine, clonazepam, and terfenadine; neither did it affect metabolism of the CYP1A2 substrate clozapine.|$|E
50|$|The {{history of}} <b>tolbutamide</b> {{has had a}} lasting effect on {{medicine}} and the pharmaceutical industry. Patients today are still diagnosed with prediabetes, many of them managing to delay the onset of diabetes through dietary and lifestyle changes, but many also {{have the option to}} take metformin, which demonstrated a 31% reduction in three-year incidence of development of diabetes relative to placebo. While impressive, the lifestyle-modification arm of that same trial demonstrated a 58% reduction.|$|E
50|$|Like other sulfonylureas, {{chlorpropamide}} acts {{to increase}} the secretion of insulin, so it is only effective in patients who have some pancreatic beta cell function. It can cause relatively long episodes of hypoglycemia; {{this is one reason}} why shorter-acting sulfonylureas such as gliclazide or <b>tolbutamide</b> are used instead. The risk of hypoglycemia makes this drug a poor choice for the elderly and patients with mild to moderate hepatic and renal impairment. Chlorpropamide is also used in partial central diabetes insipidus.|$|E
50|$|Clopidogrel {{generally}} {{has a low}} potential to interact with other pharmaceutical drugs. Combination with other drugs that affect blood clotting, such as aspirin, heparins and thrombolytics, showed no relevant interactions. Naproxen did {{increase the likelihood of}} occult gastrointestinal bleeding, as might be the case with other nonsteroidal anti-inflammatory drugs. As clopidogrel inhibits the liver enzyme CYP2C9 in cellular models, it has been theorized that it might increase blood plasma levels of drugs that are metabolized by this enzyme, such as phenytoin and <b>tolbutamide.</b> Clinical studies showed that this mechanism is irrelevant for practical purposes.|$|E
50|$|CYP2C9 is an {{important}} cytochrome P450 enzyme with {{a major role in}} the oxidation of both xenobiotic and endogenous compounds. CYP2C9 makes up about 18% of the cytochrome P450 protein in liver microsomes (data only for antifungal). Some 100 therapeutic drugs are metabolized by CYP2C9, including drugs with a narrow therapeutic index such as warfarin and phenytoin and other routinely prescribed drugs such as acenocoumarol, <b>tolbutamide,</b> losartan, glipizide, and some nonsteroidal anti-inflammatory drugs. By contrast, the known extrahepatic CYP2C9 often metabolizes important endogenous compound such as serotonin and, owing to its epoxygenase activity, various polyunsaturated fatty acids, converting these fatty acids to a wide range of biological active products.|$|E
50|$|Aspirin {{is known}} to {{interact}} with other drugs. For example, acetazolamide and ammonium chloride are known to enhance the intoxicating effect of salicylates, and alcohol also increases the gastrointestinal bleeding associated with these types of drugs. Aspirin {{is known to}} displace a number of drugs from protein-binding sites in the blood, including the antidiabetic drugs <b>tolbutamide</b> and chlorpropamide, warfarin, methotrexate, phenytoin, probenecid, valproic acid (as well as interfering with beta oxidation, {{an important part of}} valproate metabolism), and other NSAIDs. Corticosteroids may also reduce the concentration of aspirin. Ibuprofen can negate the antiplatelet effect of aspirin used for cardioprotection and stroke prevention. The pharmacological activity of spironolactone may be reduced by taking aspirin, and it is known to compete with penicillin G for renal tubular secretion. Aspirin may also inhibit the absorption of vitamin C.|$|E
50|$|The Empire {{pharmaceutical}} operation became diversified and expanded, and {{it became}} one of Canada's largest pharmaceutical companies with over 100 products in its 1964 product catalog. Empire was the first Canadian firm to license and manufacture popular medications like Valium (diazepam), Orinase (<b>tolbutamide)</b> and Tetracyn (tetracycline). The United States market was becoming a greater focus, and the U.S. military became a client, and a special manufacturing facility was being built in Puerto Rico under PRIDCO (Puerto Rico Industrial Development Company) to ship products tariff free to the US Mainland. Lou Winter also invested in Vanguard Medical Supplies, the first Canadian mail-order based pharmaceutical business with Israel Kerzner and Murray Rubin, to service rural regions via catalog mail order, and Professional Printing Services handled all of the catalog production.|$|E
50|$|In {{the summer}} of 1967, {{directly}} after completing his Ph.D. in astrophysics at MIT, Sherman purchased the Empire Group of Companies from the executor of Louis and Beverley Winter's estate, as both his aunt Beverley Winter and uncle Louis Winter had died seventeen days apart in November 1965, leaving four orphaned young children: Paul Timothy, Jeffrey Andrew, Kerry Joel Dexter, and Dana Charles. Prior to the purchase, Empire {{was the first to}} secure the compulsory rights to manufacture Hoffman-La Roche's Valium (diazepam), and was one of Canada's largest manufacturers of Pfizer's Vibramycin (tetracycline), Upjohn Company's Orinase (<b>tolbutamide),</b> and the dietary sweetener Saccharin. To facilitate the corporate acquisition, Sherman along with his high school friend, Joel Ulster (Sherman and Ulster Limited), offered five percent equity options to each of the four children and a fifteen-year royalty on four of its patented products. In 2011 the Winter children's estate sued Sherman and Royal Trust concerning the purchase of the corporate assets and brands from the Winter children's estate, alleging in court that Sherman and his partner never paid the royalties nor provided the promised equity in the businesses. As of January 2012 the case was still in court, with the plaintiffs seeking an interest in Apotex or damages of $1 billion.|$|E
5000|$|... "Developments in {{triazine}} chemistry {{continued in}} our laboratories {{under the direction}} of Shapiro...We selected betaphenyl ethyl triazine as the product to be studied for its diuretic properties. Pharmacological and toxicological studies having been completed, we were about to start clinical trials - when Lederle's Diamox broke into the market. It was obvious to us that Diamox was superior to our triazine compound and we wisely shelved the product. This left us with a fairly large stock of betaphenetheylbiguanide. We had for some time considered investigating the hypoglycemic properties of our biguanide compounds... Of the more than 260 biguanide compounds derivatized on the 1 and 1,5 nitrogens, it is unusual that of the 6 to 8 compounds found to be safe and pharmacologically active as oral hypoglycemic agents we found the very first, the betaphenethyl derivative, proved to be the most effective. The compound, with the generic name Phenformin was, after exhaustive clinical evaluation, finally chosen. After approval by the FDA, it was introduced in 1958 to the medical profession under the trade name DBI, about one year after the introduction of <b>tolbutamide,</b> the first sulfonylurea oral antidiabetic drug marketed in the US. DBI, after a modest start, has in ten years since its introduction become the second best selling oral antidiabetic drug in the United States and abroad." ...|$|E
40|$|K(ATP) -channel-dependent and K(ATP) -channel-independent insulin-releasing {{actions of}} the sulfonylurea, <b>tolbutamide,</b> were {{examined}} in the clonal BRIN-BD 11 cell line. <b>Tolbutamide</b> stimulated insulin release at both nonstimulatory (1. 1 mM) and stimulatory (16. 7 mM) glucose. Under depolarizing conditions (16. 7 mM glucose plus 30 mM KCl) <b>tolbutamide</b> evoked a stepwise K(ATP) channel-independent insulinotropic response. Culture (18 h) with <b>tolbutamide</b> or the guanidine derivative BTS 67 582 (100 microM) markedly reduced (P < 0. 001) subsequent responsiveness to acute challenge with <b>tolbutamide,</b> glibenclamide, and BTS 67 582 but not the imidazoline drug, efaroxan. Conversely, 18 h culture with efaroxan reduced (P < 0. 001) subsequent insulinotropic effects of efaroxan but not that of <b>tolbutamide,</b> glibenclamide, or BTS 67 582. Culture (18 h) with <b>tolbutamide</b> reduced the K(ATP) channel-independent actions of both <b>tolbutamide</b> and glibenclamide. Whereas culture with efaroxan exerted {{no effect on the}} K(ATP) channel-independent actions of sulfonylureas, BTS 67 582 abolished the response of <b>tolbutamide</b> and inhibited that of glibenclamide. These data demonstrate that prolonged exposure to <b>tolbutamide</b> desensitizes both K(ATP) -channel-dependent and -independent insulin-secretory actions of sulfonylureas, indicating synergistic pathways mediated by common sulfonylurea binding site(s) ...|$|E
40|$|Eight {{samples of}} human liver have been characterised for microsomal protein content, {{cytochrome}} P- 450 content, <b>tolbutamide</b> 4 -hydroxylase and ethinyloestradiol 2 -hydroxylase activities. Cytochrome P- 450 content correlated significantly with ethinyloestradiol 2 -hydroxylase activity {{but not with}} <b>tolbutamide</b> 4 -hydroxylase activity. There was no significant correlation between ethinyloestradiol 2 -hydroxylase and <b>tolbutamide</b> 4 -hydroxylase activities. The maximum <b>tolbutamide</b> 4 -hydroxylase activity was 0. 45 nmol min- 1 mg- 1 microsomal protein, with a Km value of 74 microM. A number of compounds were tested {{for their ability to}} inhibit <b>tolbutamide</b> metabolism. All the compounds showing inhibition were either non-competitive or mixed non-competitive inhibitors of <b>tolbutamide</b> 4 -hydroxylation. These studies suggest that <b>tolbutamide</b> is metabolised by an isozyme of cytochrome P- 450 which appears to be distinct from those isozymes metabolising many other drugs...|$|E
40|$|AbstractWe have {{previously}} reported that <b>tolbutamide</b> prevents the inhibition of gap junction communication in astrocytes. Here, {{we show that}} <b>tolbutamide</b> increases gap junction communication and connexin 43 expression in poorly coupled C 6 glioma cells. The increase in communication is concurrent with the inhibition of the rate of proliferation due to a block of the progression of C 6 glioma cells through the S phase of the cell cycle. The effects of <b>tolbutamide</b> were quantitatively similar to that found after the elevation of intracellular cAMP. Furthermore, the effects of <b>tolbutamide</b> and cAMP were additive. The possible beneficial effect of <b>tolbutamide</b> on gene therapy for gliomas is discussed...|$|E
40|$|The {{effect of}} {{separate}} pretreatments with cotrimoxazole, sulphamethoxazole and trimethoprim on {{the disposition of}} <b>tolbutamide</b> was studied in seven healthy males. <b>Tolbutamide</b> 500 mg intravenously was administered on four separate occasions [...] as a control without pretreatment and on the seventh day of separate twice daily administration of cotrimoxazole (sulphamethoxazole 800 mg plus trimethoprim 160 mg) (ST phase), sulphamethoxazole 1 g (S phase) and trimethoprim 150 mg (T phase). <b>Tolbutamide</b> total and unbound plasma clearance (CL) were reduced following each of the individual pretreatments compared to the control phase (P less than 0. 001). For unbound CL the reductions were 14 % in the S and T phases and 25 % in ST phase. <b>Tolbutamide</b> elimination half-life was prolonged following each pretreatment (P less than 0. 001) by 20 % in the S phase, 19 % in the T phase and 30 % in the ST phase. <b>Tolbutamide</b> total steady-state volume of distribution (VSS) was increased by 10 % in the S and ST phases (P less than 0. 01), the increase being accounted for {{by an increase in}} <b>tolbutamide</b> unbound fraction. There was no change in <b>tolbutamide</b> unbound VSS following any of the pretreatments. These results are consistent with inhibition of <b>tolbutamide</b> oxidation by cotrimoxazole, an additive effect of the two components sulphamethoxazole and trimethoprim. Sulphamethoxazole also reduces <b>tolbutamide</b> plasma protein binding...|$|E
40|$|Me{{phenytoin}}, phenytoin and <b>tolbutamide</b> are metabolised by the cytochrome P- 450 (CYP) 2 C family. Recently, it {{has been}} shown that phenytoin and <b>tolbutamide</b> are metabolised by CYP 2 C 9 / 10 whereas mephenytoin is metabolised by CYP 2 C 19. Until now, in vivo studies were only undertaken in Caucasian subjects and showed a strong relationship between phenytoin and <b>tolbutamide</b> metabolism but no significant relationship between the two drug metabolisms and that of mephenytoin. The metabolism of the three drugs was investigated in eight black Africans by urinary analysis. In this ethnic group, a strong relationship was found between phenytoin and <b>tolbutamide</b> oxidations (r(s) =- 0. 83, P= 0. 01). On the other hand, no significant relationship was found between mephentoin oxidation and phenytoin or <b>tolbutamide</b> oxidations (r(s) = 0. 31 and r(s) =- 0. 33, respectively). This study suggests that, in black Africans, phenytoin and <b>tolbutamide</b> but not mephenytoin are also hydroxylated by similar CYP enzyme(s) ...|$|E
40|$|Andrographolide is {{the most}} {{abundant}} terpenoid of A. paniculata which {{is used in the}} treatment of diabetes. In this study, we investigated the effects of A. paniculata extract (APE) and andrographolide on the expression of drug-metabolizing enzymes in rat liver and determined whether modulation of these enzymes changed the pharmacokinetics of <b>tolbutamide.</b> Rats were intragastrically dosed with 2 [*]g/kg/day APE or 50 [*]mg/kg/day andrographolide for 5 days before a dose of 20 [*]mg/kg <b>tolbutamide</b> was given. APE and andrographolide reduced the AUC 0 – 12 [*]h of <b>tolbutamide</b> by 37 % and 18 %, respectively, compared with that in controls. The protein and mRNA levels and enzyme activities of CYP 2 C 6 / 11, CYP 1 A 1 / 2, and CYP 3 A 1 / 2 were increased by APE and andrographolide. To evaluate whether APE or andrographolide affected the hypoglycemic action of <b>tolbutamide,</b> high-fat diet-induced obese mice were used and treated {{in the same manner as}} the rats. APE and andrographolide increased CYP 2 C 6 / 11 expression and decreased plasma <b>tolbutamide</b> levels. In a glucose tolerance test, however, the hypoglycemic effect of <b>tolbutamide</b> was not changed by APE or andrographolide. These results suggest that APE and andrographolide accelerate the metabolism rate of <b>tolbutamide</b> through increased expression and activity of drug-metabolizing enzymes. APE and andrographolide, however, do not impair the hypoglycemic effect of <b>tolbutamide...</b>|$|E
40|$|AbstractThe sulphonylureas {{glibenclamide}} and <b>tolbutamide</b> inhibited carnitine acyltransferase {{activities in}} rat liver microsomes. Glibenclamide {{was a more}} potent inhibitor than <b>tolbutamide.</b> The effect of <b>tolbutamide</b> on the malonyl-CoA-inhibitable transferase {{was influenced by the}} phospholipid/detergent environment whereas the effect of glibenclamide was not. Glibenclamide was a more potent inhibitor of the malonyl-CoA-inhibitable transferase than of the malonyl-CoA-insensitive enzyme. The extent of inhibition of the malonyl-CoA-inhibitable transferase by <b>tolbutamide</b> was similar to its effect on VLDL triacylglycerol secretion as reported by Wiggins and Gibbons [Biochem. J. 284 (1992) 457 – 462] possibly supporting the suggestion that microsomal carnitine acyltransferases are involved in VLDL triacylglycerol assembly/secretion...|$|E
40|$|The {{influence}} of the antidiabetic sulphonylurea <b>tolbutamide</b> on K+ channels of mouse pancreatic beta-cells was investigated using different configurations of the patch clamp technique. The dominant channel in resting cells is a K+ channel with a single-channel conductance of 60 pS that is inhibited by intracellular ATP or, in intact cells, by stimulation with glucose. In isolated patches of beta-cells membrane, this channel was blocked by <b>tolbutamide</b> (0. 1 mM) when applied to either the intracellular or extracellular side of the membrane. The dose-dependence of the tolbutamide-induced block was obtained from whole-cell experiments and revealed that 50 % inhibition was attained at approximately 7 microM. In cell-attached patches low concentrations of glucose augmented the action of <b>tolbutamide.</b> Thus, the simultaneous presence of 5 mM glucose and 0. 1 mM <b>tolbutamide</b> abolished channel activity and induced action potentials. These were not produced when either of these substances was added alone at these concentrations. The inhibitory action of <b>tolbutamide</b> or glucose on the K+ channel was counteracted by the hyperglycaemic sulphonamide diazoxide (0. 4 mM). <b>Tolbutamide</b> (1 mM) did not affect Ca 2 +-dependent K+ channels. It is concluded that the hypo- and hyperglycaemic properties of <b>tolbutamide</b> and diazoxide reflect their ability to induce the closure or opening, respectively, of ATP-regulated K+ channels...|$|E
40|$|AbstractThe {{effects of}} {{intracellular}} purine nucleotides on tolbutamide-induced block of ATP-dependent K+ channels from mouse pancreatic B-cells were studied using the patch-clamp technique. When {{applied to the}} inside of excised patches <b>tolbutamide</b> alone blocked channel activity half-maximally at 55 μM and the concentration-response curve for the inhibition of K+ channels by <b>tolbutamide</b> was flat. ADP (1 mM), but not other nucleotides (AMP, GTP or GDP) increased the steepness of the concentration-response curve and decreased the half-maximally effective <b>tolbutamide</b> concentration to 4. 2 μM. It is suggested that the ATP-dependent K+ channel or a closely related structure contains a receptor which is accessible for cytosolic ADP and controls the sensitivity to <b>tolbutamide...</b>|$|E
40|$|The rate of {{gastrointestinal}} absorption and the physiologic {{availability of}} <b>tolbutamide</b> are {{functions of the}} dissolution rate of the drug in gastrointestinal fluids. This property can be modified markedly by pharmaceutical formulation factors. The in vitro dissolution rates of clinically efficacious and clinically inefficacious <b>tolbutamide</b> tablets have been determined, {{and it has been}} found that the former dissolved considerably more rapidly than the latter. Once diabetic patients have been “titrated” with a particular brand of <b>tolbutamide</b> they should not be switched to a different brand without “retitration. ” There is need to establish an adequate in vitro test to assure the physiologic availability of <b>tolbutamide</b> from commercial tablets...|$|E
40|$|Two {{groups of}} six healthy male volunteers were studied {{to assess the}} {{possibility}} of an interaction between dextropropoxyphene and theophylline or <b>tolbutamide</b> using a randomised, crossover design. Subjects received theophylline 125 mg 8 hourly or <b>tolbutamide</b> 500 mg i. v. with and without dextropropoxyphene hydrochloride 65 mg 8 hourly. Theophylline 8 -hydroxylation was reduced by a mean of 17 % but there were no changes in theophylline 1 -demethylation, theophylline 3 -demethylation or <b>tolbutamide</b> hydroxylation...|$|E
40|$|The {{view that}} the insulinotropic {{response}} to hypoglycemic sulfonylureas is somehow related to an inhibitory action of these drugs on either the Ca 2 +-activated K+ permeability or the Na+,K+-ATPase activity in pancreatic islet cells was investigated by measuring the effect of <b>tolbutamide</b> on 86 Rb outflow and uptake, 45 Ca outflow, and insulin release in rat pancreatic islets. Although <b>tolbutamide</b> inhibited 86 Rb efflux from glucose-deprived islets, whether in the absence or presence of extracellular Ca 2 + or ouabain, a primary action of the sulfonylurea on the Ca 2 +-responsive K+ channels appeared unlikely, because <b>tolbutamide</b> failed to suppress the increase in 86 Rb outflow evoked by either the ionophore A 23187 or ouabain. Glibenclamide also failed to suppress the increase in 86 Rb outflow evoked by the ionophore. Moreover, <b>tolbutamide</b> itself stimulated quinine-sensitive 86 Rb outflow from glucose-stimulated islets. Likewise, although <b>tolbutamide</b> inhibited an ouabain-resistant modality of 86 Rb inflow into the islet cells, an inhibitory action of the sulfonylurea on the Na+,K+-ATPase appeared improbable, because <b>tolbutamide</b> failed to minimize and instead favored the cationic and secretory response to ouabain. It is concluded, therefore, that the capacity of <b>tolbutamide</b> to cause under suitable conditions continuous electrical activity in islet cells cannot be attributed to inhibition of either the Ca 2 +-sensitive K+ permeability or ouabain-sensitive Na+,K+-ATPase. Journal ArticleResearch Support, Non-U. S. Gov'tinfo:eu-repo/semantics/publishe...|$|E
40|$|Sulphonylurea {{drugs have}} been shown to protect against hypoxic damage in {{isolated}} proximal tubules of the kidney. In the present study we investigated whether these drugs can protect against hypoxic damage in a whole kidney preparation. <b>Tolbutamide</b> (200 [*]μM) and glibenclamide (10 [*]μM) were applied to the isolated perfused rat kidney prior to changing the gassing from oxygen to nitrogen for 30 [*]min. Hypoxic perfusions resulted in an increased fractional excretion of glucose (FE % glucose 14. 3 ± 1. 5 for hypoxic perfusions vs 4. 9 ± 1. 6 for normoxic perfusions, mean±s. e. mean, P< 0. 05), which could be completely restored by 200 [*]μM <b>tolbutamide</b> (5. 7 ± 0. 4 for <b>tolbutamide</b> vs 14. 3 ± 1. 5 for untreated hypoxic kidneys, P< 0. 01). Furthermore, <b>tolbutamide</b> reduced the total amount of LDH excreted in the urine (220 ± 100 [*]mU for <b>tolbutamide</b> vs 1220 ± 160 [*]mU for untreated hypoxic kidneys, P< 0. 01). Comparable results were obtained with glibenclamide (10 [*]μM). In agreement with the effect on functional parameters, ultrastructural analysis of proximal tubules showed increased brush border preservation in <b>tolbutamide</b> treated kidneys compared to untreated hypoxic kidneys. We conclude that glibenclamide and <b>tolbutamide</b> are both able to reduce hypoxic damage to proximal tubules in the isolated perfused rat kidney when applied in the appropriate concentrations...|$|E
